Pace Diagnostics
Emerging biotechnology company developing point-of-care (POC) rapid diagnostics for infectious diseases and early cancer detection. Activities described include biomarker discovery, development of cassette/strip rapid antigen and screening tests that use minimally invasive capillary blood, and steps toward manufacturing, licensing and commercialization. The organization reports grant and contract support from US federal and international public health organizations.
Industries
Nr. of Employees
small (1-50)
Pace Diagnostics
Monrovia, California, United States, North America
Products
Tuberculosis triage / screening point-of-care test
A rapid point-of-care triage/screening test intended to identify tuberculosis cases as part of early screening workflows.
COVID-19 antigen rapid detection point-of-care test
Rapid antigen detection test intended to identify SARS‑CoV‑2 infection at point of care with results in minutes.
Lung cancer early-detection test
Assay intended to detect lung cancer at earlier stages to improve treatment outcomes.
Pancreatic cancer early-detection screening (planned)
Planned early-detection test (timeline referenced for 2026) with preliminary screening data reporting ~50% sensitivity for Stage I/II and >94% specificity in initial data.
Tuberculosis triage / screening point-of-care test
A rapid point-of-care triage/screening test intended to identify tuberculosis cases as part of early screening workflows.
COVID-19 antigen rapid detection point-of-care test
Rapid antigen detection test intended to identify SARS‑CoV‑2 infection at point of care with results in minutes.
Lung cancer early-detection test
Assay intended to detect lung cancer at earlier stages to improve treatment outcomes.
Pancreatic cancer early-detection screening (planned)
Planned early-detection test (timeline referenced for 2026) with preliminary screening data reporting ~50% sensitivity for Stage I/II and >94% specificity in initial data.
Services
Diagnostics R&D and assay development
Research and development of rapid point-of-care diagnostic assays and biomarker-driven screening tests.
Clinical screening studies and validation
Preliminary screening studies to evaluate diagnostic sensitivity and specificity for early detection use cases.
Licensing, manufacturing and commercialization support
Activities supporting scale-up, manufacturing and market introduction of diagnostic tests.
Diagnostics R&D and assay development
Research and development of rapid point-of-care diagnostic assays and biomarker-driven screening tests.
Clinical screening studies and validation
Preliminary screening studies to evaluate diagnostic sensitivity and specificity for early detection use cases.
Licensing, manufacturing and commercialization support
Activities supporting scale-up, manufacturing and market introduction of diagnostic tests.
Expertise Areas
- Point-of-care diagnostic development
- Biomarker discovery and validation
- Antigen-based rapid assay development
- Cancer early-detection diagnostics
Key Technologies
- Point-of-care rapid diagnostic platforms
- Antigen immunoassays (rapid tests)
- Capillary blood-based sampling
- Cassette/strip lateral-flow–style assay formats